Jan 30th 2013 - Edison Investment Research today published a report on Adventrx Pharmaceuticals entitled "An EPIC Moment". In summary, the report says:
Adventrx has initiated patient recruitment in its pivotal Phase III study (EPIC) of ANX-188 in sickle cell disease, a significant achievement that puts the drug well ahead of its competitors. The trial design had previously been disclosed, which from an operational and statistical perspective appears to give the product an excellent chance of demonstrating a reduction in the duration of painful ‘crisis’ episodes. The rate of trial enrolment and patient dosing could have a bearing on Adventrx’s ability to secure a strategic partner and/or fresh finance required to complete the two-year study. We maintain our recently upgraded valuation of $137m or $2.50 per share.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »